SOX方案与XELOX方案治疗进展期胃癌的临床对比研究

目的 比较奥沙利铂+替吉奥(SOX)方案与奥沙利铂+卡培他滨(XELOX)方案治疗进展期胃癌(AGCA)的临床疗效.方法 选择接受化疗的AGCA患者88例,依据治疗方案分为SOX组(n=44)与XELOX组(n=44).SOX组行SOX方案化疗,XELOX组行XELOX方案化疗.比较治疗前后两组C反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)等炎性因子,CD3+、CD4+、CD8+等T淋巴细胞因子.比较两组临床疗效、不良反应及1、2、3年生存情况.结果 治疗前后,两组CRP、TNF-α、IL-6差值及CD3+、CD4+、CD8+差值比较,差异无统计学意义(P﹥0.05).SOX组PFS为(7.82±0.21)个月,XELOX组PFS为(7.69±0.18)个月,差异无统计学意义(P﹥0.05).SOX组治疗有效率(70.45%)与XELOX组治疗有效率(68.18%)比较,差异无统计学意义(P﹥0.05).SOX组1、2、3年生存率(84.09%、56.82%、40.91%)与XELOX组1、2、3年生存率(81.82%、59.09%、45.45%)比较,差异无统计学意义(P﹥0.05).SOX组手足综合征发生率(13.64%)、外周神经症状发生率(27.27%)均低于XELOX组手足综合征发生率(31.82%)、外周神经症状发生率(61.36%),差异有统计学意义(P﹤0.05).结论 SOX、XE-LOX两种方案治疗AGCA可有效杀灭肿瘤细胞,解除患者免疫抑制,促进免疫因子恢复,临床疗效均较为优异,但SOX方案不良反应发生率低,安全性更高.

A clinical comparative study comparing SOX regimen with XELOX regimen in patients with advanced gastric cancer

Objective The purpose of the study is to compare the clinical efficacy of SOX regimen with that of XELOX regimen in patients with advanced gastric cancer (AGCA). Method 88 cases of AGCA patients who were undergoing chemotherapy were enrolled and divided into SOX group (n=44) and XELOX group (n=44) according to their chemother-apy regimens. Patients in SOX group were given the chemotherapy regimen SOX comprised of Oxaliplatin plus Tega-fur, Gimeracil and Oteracil Potassium Capsules, and the patients in XELOX group were given the chemotherapy regi-men XELOX comprised of Oxaliplatin plus Capecitabine. Inflammatory factors such as C reactive protein (CRP), inter-leukin-6 (IL-6) and tumor necrosis factor-α(TNF-α) and T-lymphocyte factor such as CD3+, CD4+and CD8+were com-pared between two groups before and after treatment. The clinical efficacy, adverse reactions and 1, 2, and 3-year survival time were compared two groups. Result There were no significant differences observed in CRP, TNF-αand IL-6 values between the two groups before and after treatment (P>0.05). And there are no significant differences observed in CD3+, CD4+and CD8+values (P>0.05). The PFS values in SOX group and XELOX group are (7.82 ± 0.21) months and (7.69 ± 0.18) months respectively, and the differences did not reach statistical significance (P>0.05). The cure rates in SOX group and XELOX group are (70.45%) and (68.18%) respectively, and there was no significant difference observed (P>0.05). The differences in 1, 2 and 3-year survival rates between SOX group (84.09%, 56.82% and 40.91%, respectively) and XELOX group (81.82%, 59.09%and 45.45%, respectively) did not reach statistical significance (P>0.05). The incidences of hand-foot syndrome (13.64%) and peripheral nerve symptoms (27.27%) in the SOX group were both lower than those in XELOX group (31.82%and 61.36%, respectively), and the differences reached statistical significance (P<0.05). Con-clusion In AGCA patients, SOX and XELOX regimens can both effectively kill tumor cells, reverse immune suppres-sion, promote the recovery of immune factors, and have excellent clinical efficacy. But the SOX program has a lower inci-dence of adverse reactions and a better safety profile.